The Canadian Cancer Trials Group Central Operations and Statistics Centre will be closed on Monday, July 1, 2019 for Canada Day. Regular business hours will resume on Tuesday, July 2 at 8:30 am EDT.

Group newsletter: CCTG Connection

Archived Bulletins

June 26, 2019

Published: June 26, 2019
Category: Group updates

There is still time to register for the next CCTG New Investigator Clinical Trials Course (NICTC) being held August 7th to the 9th at the Donald Gordon Centre in Kingston, Ontario.

The NICTC is an important component of the group mandate to provide and facilitate investigator education and training. The major goal of the course is to familiarize new investigators from across the country with the essentials of clinical trial conduct in the Canadian research environment.

Read More

Published: June 26, 2019
Category: Group updates
Dr. Alex Sun as Co-Chair of Lung Disease Site Committee

Earlier this year Dr. Yee Ung stepped down from his position as the co-chair of the CCTG Lung Disease Site committee. The group convened a selection committee to choose a radiation oncologist as the new co-chair, over several months the committee solicited applications and interviewed several candidates. The members of the selection committee were: Drs. Penny Bradbury, Matthew Parliament, Andrea Bezjak, Yee Ung, and Joe Pater.

Read More

Published: June 26, 2019
Category: Group updates

Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:

Read More

A secondary methodological analysis.

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial

Economic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated.

Read More

June 12, 2019

Published: June 12, 2019
Category: Trials

IND238 (NCT03847649), A Phase II Study of Durvalumab Retreatment in Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity, has been centrally activated.

Read More

Published: June 12, 2019
Category: Group updates

The Office of Compliance and Oversight released an updated Good Clinical Practice training course, that includes Revision 2. The revised GCP training course is available for new members who have not yet trained in GCP. A GCP refresher module, including the Revision 2 updates, was created for members who have previously completed a GCP training course. GCP training will be valid for three years from the date of completion. This training is mandatory for all members conducting clinical trials per CCTG SOPs and in compliance with NIH policy.

Read More

Clinical Research Associate (CRA) Volunteer Needed for the Breast, Gastrointestinal and Gynecologic Disease Site Executive!

The Canadian Cancer Trials Group is actively seeking CRA representatives from Canadian Member sites to sit on the Breast, Gastrointestinal and Gynecologic Disease Site Committee Executives.

Read More

Published: June 12, 2019
Category: News

At ASCO 2019 the landmark ENZAMET | CCTG PR17 (NCT02446405) clinical trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer. Findings, show that men with this sort of cancer who receive enzalutamide with standard treatment have a 33% improvement in survival compared to men receiving standard treatment alone.

Read More